The combination of the PARP inhibitor talazoparib and the immune checkpoint inhibitor atezolizumab as maintenance therapy significantly improved the progression-free survival (PFS) of patients with SLFN11-positive small cell lung cancer (SCLC) (39). Here, SLFN11 is linked to small cell lung carcinoma.